AngioDynamics’ (ANGO) Buy Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of AngioDynamics (NASDAQ:ANGO) in a report published on Friday, MarketBeat Ratings reports. They currently have a $14.00 price target on the medical instruments supplier’s stock. HC Wainwright also issued estimates for AngioDynamics’ FY2026 earnings at ($0.26) EPS.

Separately, Canaccord Genuity Group dropped their price target on shares of AngioDynamics from $13.00 to $12.00 and set a buy rating on the stock in a research note on Friday.

AngioDynamics Stock Performance

AngioDynamics stock opened at $6.10 on Friday. The company has a fifty day simple moving average of $7.44 and a 200-day simple moving average of $6.64. The stock has a market cap of $244.34 million, a P/E ratio of -1.26 and a beta of 0.65. AngioDynamics has a 12-month low of $5.26 and a 12-month high of $8.25.

AngioDynamics (NASDAQ:ANGO) last released its quarterly earnings data on Thursday, October 3rd. The medical instruments supplier reported ($0.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.15) by $0.04. AngioDynamics had a negative return on equity of 4.91% and a negative net margin of 61.55%. The business had revenue of $67.50 million during the quarter, compared to analysts’ expectations of $67.93 million. During the same period in the prior year, the firm posted ($0.12) EPS. The business’s quarterly revenue was down 14.2% compared to the same quarter last year. As a group, sell-side analysts forecast that AngioDynamics will post -0.41 earnings per share for the current fiscal year.

Hedge Funds Weigh In On AngioDynamics

Several hedge funds have recently made changes to their positions in ANGO. Systematic Financial Management LP boosted its position in shares of AngioDynamics by 8.4% in the 2nd quarter. Systematic Financial Management LP now owns 2,109,561 shares of the medical instruments supplier’s stock valued at $12,763,000 after purchasing an additional 162,972 shares during the period. Millennium Management LLC boosted its holdings in shares of AngioDynamics by 41.9% in the second quarter. Millennium Management LLC now owns 1,793,454 shares of the medical instruments supplier’s stock valued at $10,850,000 after acquiring an additional 529,861 shares during the period. Acadian Asset Management LLC boosted its holdings in shares of AngioDynamics by 11.9% in the first quarter. Acadian Asset Management LLC now owns 1,012,186 shares of the medical instruments supplier’s stock valued at $5,940,000 after acquiring an additional 107,764 shares during the period. Western Standard LLC grew its position in shares of AngioDynamics by 878.5% during the first quarter. Western Standard LLC now owns 523,393 shares of the medical instruments supplier’s stock worth $3,072,000 after acquiring an additional 469,906 shares during the last quarter. Finally, Fund 1 Investments LLC acquired a new position in shares of AngioDynamics in the 4th quarter valued at $3,896,000. Hedge funds and other institutional investors own 89.43% of the company’s stock.

AngioDynamics Company Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.